Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females

Vaccine

Volumn 30, Issue 28, 2012, Pages 4284-4291

  Li, Rongcheng ^a   Li, Yanping ^a   Radley, David ^b   Liu, Youping ^c   Huang, Teng ^a   Sings, Heather L ^b   Zhang, Lingling ^d   Wang, Wei ^d   Zhong, Xiang ^d   Saah, Alfred J ^b  

^a GUANGXI CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b MERCK RESEARCH LABORATORIES   (United States)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Hangzhou MSD Pharmaceutical Co Ltd   (China)

Author keywords

Cervical cancer; Human papillomavirus; Prevention; Randomized trial; Vaccine

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ALLERGIC REACTION; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CHILD; CHINA; CHINESE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UPPER RESPIRATORY TRACT INFECTION; UTERINE CERVIX CANCER; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; CHINA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PLACEBOS; YOUNG ADULT;

EID: 84862823358     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.079     Document Type: Article

References (31)

1. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997, 102:3-8.
2. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
3. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsaguë X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
4. Muñoz N., Castellsague X., de Gonzalez A.B., Gissmann L. HPV in the etiology of human cancer. Vaccine 2006, 24:S1-S10.
5. Fakhry C., Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006, 24:2606-2611.
6. Lacey C.J., Lowndes C.M., Shah K.V. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24:S35-S41.
7. X. Castellsagué, S. de Sanjosé, T. Aguado, K.S. Louie, L. Bruni, J. Muñoz, et al. HPV and cervical cancer in the word. 2007 report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV information centre). Available from: 2009.[cited 10.05.10]. http://www.who.int/hpvcentre.
8. Kim K., Zang R., Choi S.C., Ryu S.Y., Kim J.W. Current status of gynecological cancer in China. J Gynecol Oncol 2009, 20:72-76.
9. The L. Women's health in rural China. Lancet 2009, 374:358.
10. Chen W., Zhang X., Molijn A., Jenkins D., Shi J.F., Quint W., et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009, 20:1705-1713.
11. Wang H., Qiao Y.L. Human papillomavirus type-distribution in condylomata acuminata of mainland China: a meta-analysis. Int J STD AIDS 2008, 19:680-684.
12. Wu R.F., Dai M., Qiao Y.L., Clifford G.M., Liu Z.H., Arslan A., et al. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer 2007, 121:1306-1311.
13. Zhao F., Li N., Ma J. Study of the association between human papillomavirus infection and cervical cancer in Xianguan county, Shanxi province. Zhonghua Liu Xing Bing Xue Za Zhi 2001, 22:375-378.
14. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
15. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
16. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927. The FUTURE II Study Group.
17. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011, 364:401-411.
18. Tay E.H., Garland S., Tang G., Nolan T., Huang L.M., Orloski L., et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. Int J Gynaecol Obstet 2008, 102:275-283.
19. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6:271-278.
20. Dias D., Van Doren J., Schlottmann S., Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005, 12:959-969.
21. Barr E., Gause C.K., Bautista O.M., Railkar R.A., Lupinacci L.C., Insinga R.P., et al. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol 2008, 198:261-311.
22. Perez G., Lazcano-Ponce E., Hernandez-Avila M., Garcia P.J., Munoz N., Villa L.L., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 2008, 122:1311-1318.
23. Majewski S., Bosch F.X., Dillner J., Iversen O.E., Kjaer S.K., Munoz N., et al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16-24. J Eur Acad Dermatol Venereol 2009, 23:1147-1155.
24. Giuliano A., Lazcano-Ponce E., Villa L., Nolan T., Marchant C.D., Radley D., et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 2007, 196:1153-1162. (© 2007 by the Infectious Diseases Society of America).
25. Paavonen J. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials. Curr Med Res Opin 2008, 24:1623-1634.
26. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
27. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
28. Munoz N., Manalastas R., Pitisuttihum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women between 24 and 45 years of age: a randomized, double-blind trial. Lancet 2009, 373:1949-1957.
29. Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer 2007, 96:1320-1323.
30. Olsson S-E., Villa L.L., Costa R., Petta C., Andrade R., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like-particle vaccine. Vaccine 2007, 25:4931-4939.
31. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Paavonen J., Iversen O.-E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.